CLAIMS

1. Use of varying concentrations of Calebin-A in the manufacture of a medicament to treat high fat diet (HFD) induced hepatic steatosis associated with non alcoholic fatty liver disease or non-alcoholic steatohepatitis wherein Calebin A attenuates hepatic inflammatory infiltration and hepatocellular ballooning degeneration.